Ruey-min Lee

发表

Analysis of gene expression during myc oncogene-induced lymphomagenesis in the bursa of Fabricius

P. Neiman, A. Ruddell, C. Jasoni, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Molecular events in avian neoplasia: Regulators of cell death in development of B‐cell lymphomas in the chicken bursa of Fabricius

P. Neiman, Ruey-min Lee, G. Gillet, 1998 .

Time‐to‐event modelling of effect of codrituzumab on overall survival in patients with hepatocellular carcinoma

Ruey-min Lee, G. Abou-Alfa, C. Diack, 2018, British journal of clinical pharmacology.

The Synthetic Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic Acid Induces Caspase-Dependent and -Independent Apoptosis in Acute Myelogenous Leukemia

M. Sporn, J. Belmont, Ruey-min Lee, 2004, Cancer Research.

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Ruey-min Lee, S. Ou, Gregory Riely, 2014, The Lancet. Oncology.

Role of Mtd/Bok in normal and neoplastic B-cell development in the bursa of Fabricius.

P. Neiman, Ruey-min Lee, Cheryl Y. Brown, 2004, Developmental and comparative immunology.

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.

J. Blay, Ruey-min Lee, G. Demetri, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The apoptotic effect of HA14-1, a Bcl-2-interacting small molecular compound, requires Bax translocation and is enhanced by PK11195.

Ruey-min Lee, Q. Dai, Jihua Liu, 2002, Molecular cancer therapeutics.

A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas

Wolfgang Sadee, Charis Eng, Lai Wei, 2009, Clinical Cancer Research.

A Phase II study of the efficacy and tolerability of Lapatinib in patients with advanced hepatocellular carcinomas.

M. Grever, Ruey-min Lee, N. Heerema, 2008 .

Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma.

Ruey-min Lee, T. Bekaii-Saab, D. Sullivan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of AZD6244 in advanced or metastatic hepatocellular carcinoma.

Ruey-min Lee, T. Bekaii-Saab, A. Deal, 2016, Journal of Clinical Oncology.

A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas

M. Grever, Ruey-min Lee, N. Heerema, 2009, Clinical Cancer Research.